Criteria for the clinical use of immunogloulin
Posted 1 year ago
The criteria is changing:
- To align with new evidence
- To ensure those whose health is most likely to be improved with Ig therapy can get it
- To manage the growth in demand for this precious, human-derived product.
Some current authorisations will move to the new Criteria automatically, while others may require prescribers to provide more information at the next patient review.
For more information please visit the National Blood Authority website.